Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

Delayed Quote. Delayed  - 09/23 10:00:15 pm
62.96 USD   -0.10%
09/23DJMERCK : Keytruda Finds Fast Entry Into China Via Medical-Tourism Pus..
09/23 MERCK : to Hold Third-Quarter 2016 Sales and Earnings Conference Cal..
09/21 MERCK : Geneva Advisors Lowers stake in Merck & Co. (MRK)
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

US Judge Upholds Validity Of Merck's Vytorin Patent

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/28/2012 | 12:29am CEST

--Judge rules U.S. patent for Vytorin and Zetia is valid and enforceable

--Mylan had challenged patent in bid to sell generic Vytorin and Zetia

--Merck patent due to expire in April 2017

(Adds statement from Merck, additional details.)

 
   By Peter Loftus 
   Of  
 

A federal judge has upheld the validity of a U.S. patent covering Merck & Co.'s (>> Merck & Co., Inc.) cholesterol-lowering drugs Vytorin and Zetia, which could stave off competing generic copies for several years.

In an opinion released Friday, U.S. District Judge Jose Linares in federal court in Newark, N.J., said the patent for was valid and enforceable. The patent covers ezetimibe, an active ingredient in both Zetia and Vytorin.

Merck, based in Whitehouse Station, N.J., said the U.S. patent for Vytorin and Zetia is due to expire in April 2017.

"The court appropriately ruled that the patent for Zetia and Vytorin in the U.S. is valid and enforceable," Bruce N. Kuhlik, executive vice president and general counsel of Merck, said in a press release.

Mylan Inc. (MYL) had applied for U.S. Food and Drug Administration approval to sell generic versions of Vytorin and Zetia before the patent expired, arguing that the patent was invalid and unenforceable.

Merck filed a patent-infringement lawsuit against Mylan in late 2009, seeking to block Mylan's plan to sell generic Vytorin, and in 2010 sued to block Mylan from selling generic Zetia. A trial was held in December 2011, leading to Judge Linares's opinion Friday.

Merck said the court also issued an injunction blocking the approval of Mylan's generic versions until the expiration of the patent.

A Mylan spokeswoman couldn't immediately be reached for comment.

Earlier Friday, Merck reported first-quarter Vytorin sales of $444 million and Zetia sales of $614 million.

Merck previously reached a settlement of patent litigation for Zetia with generics manufacturer Glenmark Pharmaceuticals. The pact will allow Glenmark to sell generic Zetia in December 2016, subject to final regulatory approval.

-By Peter Loftus, Dow Jones Newswires; 215-982-5581; peter.loftus@dowjones.com

Stocks mentioned in the article : Merck & Co., Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on MERCK & CO., INC.
09/23DJMERCK : Keytruda Finds Fast Entry Into China Via Medical-Tourism Push
09/23 MERCK : to Hold Third-Quarter 2016 Sales and Earnings Conference Call on October..
09/21 MERCK : Geneva Advisors Lowers stake in Merck & Co. (MRK)
09/20 MERCK : to Host Investor Teleconference to Discuss ESMO 2016 Highlights
09/20 Bayer raises sales targets for top-selling drugs after Monsanto deal
09/20DJBusiness Watch -- WSJ
09/20DJBullish Bayer Boss Defends Monsanto Deal
09/20 Britain's May meets Goldman, Amazon, IBM to discuss post-Brexit investment
09/19DJSANOFI : Files Suit Against Merck, Claiming Patent Infringements -Update
09/19DJSanofi Files Suit Against Merck
More news
Sector news : Pharmaceuticals - NEC
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira
09/23 Endo International CEO steps down, Campanelli named successor
09/23DJSHIRE : Files 8K - Direct Or Off-Balance Sheet Financial Obligation
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
09/23 Industrial Sector Capped By Ships & Ports In September
09/23 Agenus' Immuno-Oncology Pipeline Has Promise
09/22 BIONOMICS : No Longer Depressed, Opportunity Knocks
09/22 Expect Glaxo To Increase Consumer Focus As Walmsley Takes Driving Seat
09/21 Cerecor completes enrollment in mid-stage study of MDD candidate CERC-301
Advertisement
Financials ($)
Sales 2016 39 719 M
EBIT 2016 13 608 M
Net income 2016 5 662 M
Debt 2016 5 481 M
Yield 2016 2,89%
P/E ratio 2016 30,56
P/E ratio 2017 20,70
EV / Sales 2016 4,52x
EV / Sales 2017 4,46x
Capitalization 174 098 M
More Financials
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 66,1 $
Spread / Average Target 5,0%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis Chief Financial Officer & Executive Vice President
Michael A. Rosenblatt Chief Medical Officer & Executive Vice President
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.19.20%174 098
JOHNSON & JOHNSON15.66%325 050
ROCHE HOLDING LTD.-11.32%218 395
NOVARTIS AG-8.70%214 744
PFIZER INC.6.13%207 809
GLAXOSMITHKLINE PLC20.39%104 476
More Results